Vascular endothelial growth factor before and after locoregional treatment and its relation to treatment response in hepatocelluar carcinoma patients

详细信息    查看全文

• 作者：Heba Sedrak¹ ; ^{drhebasedrak@yahoo.com" class="auth_mail" title="E-mail the corresponding author} ; Noaman El-Garem¹ ; Mervat Naguib¹ ; Heba El-Zawahry² ; Mohamed Esmat² ; Lila Rashed³
• 关键词：Hepatocelluar carcinoma ; Vascular endothelial growth factor ; Percutaneous ethanol injection ; Transcatheter arterial chemoembolization
• 刊名：Asian Pacific Journal of Tropical Biomedicine
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：5
• 期：12
• 页码：1005-1009
• 全文大小：309 K

文摘

To evaluate vascular endothelial growth factor (VEGF) levels in hepatocellular carcinoma patients before and after transcatheter arterial chemoembolization (TACE) and percutaneous ethanol injection (PEI) and its relation to treatment response.

Methods

A total of 40 patients with unrespectable hepatocelluar carcinoma were assessed clinically. Twenty patients were suitable to be treated by TACE, while other 20 patients were treated with PEI. Serum VEGF levels were measured before and 1 month after each procedure by ELISA. Response was assessed after 1 month according to Union Internationale Contre le Cancer evaluation criteria based on change in tumor size as measured by ultrasound.

Results

There was no significant difference between TACE and PEI groups with regard to age, sex, tumor size, response to local therapy, or VEGF and alpha-fetoprotein before and after therapy. VEGF levels after TACE were significantly higher than before TACE [(298.1 ± 123.6) pg/mL vs. (205.8 ± 307.3) pg/mL; P = 0.001]. Also, VEGF levels were significantly higher after PEI than before PEI [(333.8 ± 365.6) pg/mL vs. (245.3 ± 301.8) pg/mL; P = 0.000]. Non-responders of both groups had significantly high VEGF levels than responder's, both before [(985.0 ± 113.2) pg/mL vs. (117.1 ± 75.3) pg/mL; P < 0.001] and after therapy [(1 330.6 ± 495.7) pg/mL vs. (171.0 ± 94.7) pg/mL; P = 0.000)].

Conclusions

Both TACE and PEI were associated with an increase in serum VEGF in hepatocelluar carcinoma patients. Higher levels of VEGF before and after therapy were found in non-responders, suggesting that VEGF is a useful marker in predicting treatment response.